ONE-TWENTY TWO: Trading Financial Markets
Exploring the poetry in financial markets for students of money and economy since the year 2000.
The angst may already be fading away. Last week, I chronicled the carnage across the stocks of home builders that erupted in response to the Republican plan for tax reform that includes a reduction in the cap on the mortgage interest deduction. The sell-off that likely had roots in the extreme displeasure emanating from the … Read more
I last wrote about earnings from KB Home (KBH) well over a year ago. While I kept tabs on the stock through my Housing Market Reviews, I never set up specific decision points for getting back into the stock. I finally created a decision point on October 12th when I made a hedged play of … Read more
On August 15, 2017, I had the privilege of interviewing Bill Sandbrook, President and CEO of U.S. Concrete (USCR), a producer of ready-mixed concrete and aggregate products for domestic construction projects. I am relatively new to this industry, so I prepared by listening to earlier interviews, reviewing USCR’s latest earnings results for Q2 2017, and … Read more
As North Korean President Kim Jung Un and U.S. President Donald Trump shot barbs and threats at each other – threats which included Trump’s promises of fire and fury and perhaps more – ShotSpotter (SSTI), a gunfire detection and location technology company, reported earnings. I think the promising results were lost in the crossfire and … Read more
Teva Pharmaceuticals (TEVA) lost 24% last Thursday after reporting disappointing earnings. From the Seeking Alpha transcript of the conference call: “All of us at Teva understand the frustration and disappointment our shareholders are feeling… In our U.S. Generics business, we experienced accelerated price erosion and decreased volume, mainly due to customer consolidation, greater competition as … Read more